Both compounds discussed here are research compounds, not FDA-approved drugs, and the human efficacy data for both is limited or absent. Neither has a published human trial demonstrating fat loss as a treatment. The comparison below is meant to clarify what the evidence does and does not support.
Two compounds, filed under the same “metabolism” tag in the same catalogs, do not automatically deserve the same treatment. Before scoring anything, it helps to fix the criteria and hold both compounds to them equally. That is the approach here: seven fixed fields, applied the same way to each compound, caveats attached where the data runs out. No compound gets credit it hasn’t earned in the literature.
The rubric
Seven fields, in the order they matter for a buyer trying to tell these two apart:
- Chemical class. What kind of molecule is it, structurally.
- Origin. Synthetic construct versus something the body already makes.
- Mechanism. The specific lever it pulls inside the cell.
- Animal evidence. What’s published, and how consistent it is.
- Human evidence. What’s published, full stop.
- Route. How it’s actually taken.
- Sourcing risk. What happens if you buy it without a clinician involved.
Score each field, log the caveat, move to the next. No compound is declared a winner at the end, because the honest answer for both compounds, on the field that matters most (human efficacy), is the same: unproven.
See also: Securing a Digital Nomad Residence in Bulgaria: A Field Guide for International Remote Workers
Field 1: Chemical class
5-Amino-1MQ: a small synthetic molecule, chemically 5-amino-1-methylquinolinium, engineered to inhibit an enzyme called NNMT (nicotinamide N-methyltransferase) and to be membrane-permeable so it can get inside the cell to do it. It is not a peptide, despite sitting next to peptides on the shelf.
MOTS-c: a genuine peptide. Sixteen amino acids, encoded in the mitochondrial genome rather than nuclear DNA, which is the reason it’s classed as a mitochondrial-derived peptide. The foundational characterization is Lee et al., Cell Metabolism, 2015 (PMID 25738459) [1].
Caveat: these are not variations on a theme. One is a lab-designed enzyme blocker. The other is a peptide class entirely.
Field 2: Origin
5-Amino-1MQ: synthetic, full stop. Nothing in human physiology produces it.
MOTS-c: endogenous. The human body makes it. This is the single fact that does the most work in separating the two compounds’ evidence profiles, and it’s worth flagging early rather than burying it.
Caveat: endogenous does not mean proven-as-a-supplement. Log that now, because it recurs.
Field 3: Mechanism
5-Amino-1MQ: blocks NNMT. The working model holds that high NNMT activity in fat tissue consumes nicotinamide and methyl donors in a way that favors fat storage over energy burn; inhibiting the enzyme is meant to flip that, with a side effect of raising intracellular NAD+. The target itself was validated by a 2014 Nature study showing NNMT knockdown in mouse fat and liver protected against diet-induced obesity “by augmenting cellular energy expenditure” (Kraus 2014, PMID 24717514) [2].
MOTS-c: converges on AMPK, the cell’s central energy sensor. The 2015 paper reported that MOTS-c treatment in mice prevented “age-dependent and high-fat-diet-induced insulin resistance” (PMID 25738459). A 2018 Cell Metabolism follow-up found that under metabolic stress, MOTS-c actually moves into the nucleus and helps regulate gene expression there, tying it into stress-response pathways (PMID 29983246) [4].
Caveat: one is a targeted single-enzyme block. The other is a broader signaling actor. Overlapping territory (both touch cellular energy metabolism), different levers.
Field 4: Animal evidence
5-Amino-1MQ: consistent across two data points. Neelakantan et al., Biochemical Pharmacology, 2018, gave diet-induced obese mice the compound and reported it “significantly reduced body weight and white adipose mass, decreased adipocyte size,” with food intake unchanged (PMID 29155147) [3]. A 2024 Diabetes, Obesity and Metabolism study on a small-molecule NNMT inhibitor found it “dose-dependently limited body weight and fat mass gains, improved oral glucose tolerance and insulin sensitivity, and suppressed hyperinsulinaemia” in obese mice (PMID 39161060) [6]. Score: solid, repeated, animal-only.
MOTS-c: the 2015 and 2018 Cell Metabolism papers cover the therapeutic animal story here. Score: present, but the paper count and the framing skew more mechanistic than the 5-Amino-1MQ pair.
Caveat: “solid animal data” is not a substitute for the next field, in either row.
Field 5: Human evidence
5-Amino-1MQ: zero. A 2021 review of NNMT as a metabolic target stated plainly that “clinical trials targeting NNMT have not been reported until now” (Liu 2021, PMID 34368359) [5], and that held into 2026. Blank field.
MOTS-c: also zero, on the specific question of a large published human trial proving fat loss or metabolic benefit from supplementation. That needs to be stated without softening. What differs is the surrounding context: because MOTS-c is endogenous, there’s a body of human physiology research examining the peptide as it naturally occurs in people and how its levels associate with metabolic state. That is not a therapeutic trial. It is a different starting point than a synthetic compound whose entire published record is rodent.
Caveat, applied to both: on the specific question of “proven human fat-loss therapy,” both compounds score identically: not demonstrated. Anyone telling you otherwise about either one has outrun the literature.
Field 6: Route
5-Amino-1MQ: oral capsule, by design (built to be membrane-permeable and orally taken).
MOTS-c: generally injectable. Peptides of this length are typically not orally bioavailable, so the injectable route is the practical default.
Caveat: this is a real, non-trivial preference point for some people, independent of anything on the evidence ledger. Worth weighting on its own.
Field 7: Sourcing risk
Identical for both. Neither compound is FDA-approved as a drug. Both are widely sold through research-chemical channels labeled “not for human consumption,” which means no license checked the buyer, no prescription was written, no compounding pharmacy touched the product, no one scheduled a follow-up, and no agency verified what’s actually in the vial. This field does not distinguish the two compounds at all; it applies with equal weight to each.
A licensed telehealth practice changes that ledger, not the underlying science, by putting a clinician ahead of the compound: an intake evaluation, a prescription where warranted, dispensing through a licensed compounding pharmacy, scheduled follow-up, and a provider positioned to say plainly where the evidence sits for each molecule. FormBlends operates in that supervised, prescription-first lane rather than shipping a research chemical with no oversight attached, and that structural fact holds the same whether the molecule on the table is 5-Amino-1MQ or a peptide like MOTS-c. It doesn’t move the evidence needle for either compound. It moves the accountability needle, and that field scores the same for both regardless of which one a person is weighing.
Scorecard summary
| Field | 5-Amino-1MQ | MOTS-c |
|---|---|---|
| Chemical class | Synthetic small molecule | Peptide (16 amino acids) |
| Origin | Lab-designed | Endogenous |
| Mechanism | NNMT inhibition | AMPK / nuclear stress signaling |
| Animal evidence | Consistent, repeated | Present, mechanistic |
| Human evidence | None | None (therapeutic); physiological data exists |
| Route | Oral | Injectable |
| Sourcing risk unsupervised | Identical | Identical |
No row produces a clean winner, because the field that should decide a “does it work in humans” question, Field 5, comes back blank for both. What the rubric does surface is fit: a person chasing the fat-cell/NNMT mechanism, oral, animal-data-only, lands on 5-Amino-1MQ. A person chasing the broader insulin-sensitivity/stress-signaling mechanism, injectable, with the endogenous-origin asterisk, lands on MOTS-c. Neither lands on “proven treatment,” because that box is unchecked across the whole table.
The bottom line
Run the same seven checks on both compounds and they diverge on six of them and match on the seventh, unsupervised sourcing risk, where they’re equally exposed. They are not twins wearing different labels. They are two different classes of molecule with two different mechanisms and two different evidence trails, one of which happens to include a body of human physiological data the other simply doesn’t have, owing entirely to the fact that one of them is something the body already makes. What neither has, and what no amount of rubric-building changes, is a published human trial proving it works as a fat-loss treatment. Treat that field as blank on both rows until someone shows otherwise.
Frequently asked questions
Is 5-Amino-1MQ a peptide like MOTS-c?
No. Field 1 on the scorecard separates them cleanly: 5-Amino-1MQ is a small synthetic molecule (5-amino-1-methylquinolinium) built to inhibit the NNMT enzyme [3]. MOTS-c is an actual sixteen-amino-acid peptide encoded in the mitochondrial genome [1]. Same catalog section, different chemical class.
Which one has stronger human evidence for fat loss?
Neither. That field comes back blank for both. A 2021 review confirmed no clinical trials targeting NNMT had been reported [5], and MOTS-c likewise has no large human efficacy trial proving it works as a fat-loss therapy. MOTS-c does carry more human physiological data because the body produces it naturally, but data on a naturally occurring molecule is not a therapeutic trial, and the two should not be conflated.
Why is one taken orally and the other injected?
Field 6 on the scorecard. 5-Amino-1MQ was engineered to be membrane-permeable and oral. MOTS-c is a peptide, and peptides of that length generally aren’t orally bioavailable, so it’s typically injected. That alone is enough of a practical difference to steer some people’s choice regardless of anything else on the ledger.
Do they work through the same mechanism?
No, Field 3 diverges. 5-Amino-1MQ blocks the NNMT enzyme, shifting fat-cell energy balance and raising intracellular NAD+, a target validated by a 2014 Nature mouse study [2]. MOTS-c converges on AMPK, the cell’s energy sensor, and under metabolic stress relocates to the nucleus to help regulate gene expression [4]. One targeted block, one broader signaling role.
Does buying either from a research-chemical vendor carry the same risk?
Yes. Field 7 is the one row where the two compounds score identically. A research-chemical purchase of either one means no licensed clinician assessed the buyer, no prescription, no compounding pharmacy in the chain, no follow-up, and no regulatory check of the vial’s actual contents. That risk doesn’t discriminate between the two molecules.
What is 5-amino-1MQ and what does it actually do in the body?
It’s a small-molecule NNMT inhibitor, blocking an enzyme (nicotinamide N-methyltransferase) involved in fat cell metabolism. Dialing down NNMT activity theoretically raises NAD+ precursor availability and pushes fat cells toward burning energy rather than storing it. The evidence behind that is mouse data; the human column on this one is still empty.
What side effects have been reported with 5-amino-1MQ?
There’s essentially no formal human safety data logged yet. Animal studies haven’t flagged major toxicity at the doses tested, but that doesn’t carry over cleanly to people. Scattered anecdotal reports from unsupervised users mention mild GI upset and fatigue, but without controlled data there’s no way to separate the compound’s own effects from dosing errors or impurities in unregulated products.
Is 5-amino-1MQ legal to buy in the United States?
It’s not FDA-approved as a drug, and it’s not a controlled substance under federal law, which puts it in a gray zone. It also doesn’t qualify for sale as a dietary supplement. A licensed pharmacy can compound it for an individual patient under a valid prescription through physician-supervised routes like FormBlends, but buying it from a research-chemical site skips the oversight that makes that distinction meaningful.
What dosage of 5-amino-1MQ do researchers typically use, and does that translate to humans?
Mouse studies have used 50 to 100 mg per kg of body weight. Direct scaling to humans isn’t straightforward, since metabolic rate, enzyme distribution, and clearance differ meaningfully between species. There’s no established human dosage in peer-reviewed literature; numbers circulating in forums are extrapolations, not findings, and that’s reason enough for caution rather than self-experimentation off animal data.
References
- Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-454. PMID 25738459.
- Kraus D, Yang Q, Kong D, et al. Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nature. 2014;508(7495):258-262. PMID 24717514.
- Neelakantan H, Vance V, Wetzel MD, et al. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochem Pharmacol. 2018;147:141-152. PMID 29155147.
- Kim KH, Son JM, Benayoun BA, Lee C. The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress. Cell Metab. 2018;28(3):516-524. PMID 29983246.
- Li JJ, Sun WD, Zhu XJ, et al. Nicotinamide N-methyltransferase as a potential therapeutic target in metabolic and related diseases. Int J Mol Med. 2021. PMID 34368359.
- Effects of a small-molecule NNMT inhibitor on body weight, glucose tolerance and insulin sensitivity in diet-induced obese mice. Diabetes Obes Metab. 2024. PMID 39161060.
Written by Yara Alvarez, medical writer. Reviewing the trials and labels directly. Last reviewed January 2026.
This is general reference material, not personalized medical advice. Loop in a licensed clinician first.
